Abstract
Xuezhikang (XZK) is an extract derived from red yeast rice that is commonly used to treat cardiovascular conditions as a traditional Chinese medicine, both within China and globally. Genotoxicity, acute toxicity, and a 26-week toxicity study in rat have been reported in our previous publication. The present study was designed to assess the long-term safety of XZK when administered orally to dogs. Dogs were treated with encapsulated XZK at a maximum dose of 2000 mg/kg followed by 1000 mg/kg and 500 mg/kg (n = 6/sex/group) for this 26-week oral toxicity study. Control animals were given an empty capsule. Treated animals were then monitored through measurements of body weight, body temperature, food intake, ophthalmic and electrocardiogram examinations, general clinical observations, mortality rates, and clinical and anatomic pathological findings. Additionally, blood samples were collected and used to conduct hematological and biochemical analysis. Several abnormalities were found in all groups including: fecal abnormalities (including mucoid, poorly formed, or liquid feces). Moreover, reduced CHOL and TRIG values were seen in all XZK groups (p < 0.05), increased WBC and NEUT levels in 500 mg/kg group (males only, p < 0.05), and elevated AST, ALT, and ALP activities in 2000 mg/kg group (p < 0.05). These changes were resolved in the recovery period. The results indicated that XZK may temporarily impact the liver enzyme levels, but were not considered adverse effects. These findings yielded a NOAEL for XZK in dogs of 2000 mg/kg.
Full text
